The two FDA-approved apps – RESET and RESET-O – have been re-launched by new owner PursueCare, which acquired them as part of ...

Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU ...

The pharmaceutical industry faces an urgent challenge: frequent drug shortages that threaten patient care and public health. These shortages disrupt treatment, elevate patient anxiety, and, in ...

Generative AI (GenAI) technology is already transforming everyday regulatory and safety processes, thanks to its ability to digest, assess, and summarise key insights and findings from across vast ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

As has been widely acknowledged, one of the most meaningful steps a business can take is to establish a single point of contact that permits one set of communications, with the whole of a client ...

September is the perfect time to turn up the volume on conversations about Primary Biliary Cholangitis (PBC) and the symptoms people living with it experience, in support of PBC Awareness Month.

Rebecca Douglas is a strategic leader with a passion for nurturing talent. With an award-winning track record in developing and managing training programmes at IPG Health Medical Communications ...

The US Food and Drug Administration (FDA) has provided an ‘at-a-glance’ summary of the agency’s news. Seven new clinical trial grants were awarded under the Orphan Product Grants Program ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...

The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a "perverse drug rebate system" that it claims artificially inflated the prices ...

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.